Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 15;16(20):3488.
doi: 10.3390/cancers16203488.

Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

Aaron M Lee  1 , Alice N Weaver  1 , Phillip Acosta  2 , Lauren Harris  3 , Daniel W Bowles  1   4
Affiliations
Review

Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma

Aaron M Lee et al. Cancers (Basel). .

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a complex cancer requiring a multidisciplinary approach. For patients with locally or regionally advanced disease, surgery and/or radiation are the cornerstones of definitive treatment. Medical therapy plays an important adjunct role in this setting, typically consisting of a platinum-based regimen given as induction, concurrent, or adjuvant treatment. While relapsed/metastatic HNSCC has historically been a difficult-to-treat disease with poor outcomes, options have considerably improved with the incorporation of biologics and immune checkpoint inhibitors. Clinical trials are ongoing to investigate novel approaches, including new and combination immunotherapies, targeted therapies, therapeutic vaccines, antibody-drug conjugates, and cellular therapies. The results thus far have been mixed, highlighting the knowledge gaps that continue to challenge the medical oncologist treating HNSCC. Here, we present the most updated and broad review of the current treatment landscape in both locoregional and metastatic HNSCC and discuss the expansive future medical therapies under investigation.

Keywords: head and neck squamous cell carcinoma; immunotherapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Barsouk A., Aluru J.S., Rawla P., Saginala K., Barsouk A. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med. Sci. 2023;11:42. doi: 10.3390/medsci11020042. - DOI - PMC - PubMed
    1. Carey R.M., Fathy R., Shah R.R., Rajasekaran K., Cannady S.B., Newman J.G., Ibrahim S.A., Brant J.A. Association of Type of Treatment Facility With Overall Survival After a Diagnosis of Head and Neck Cancer. JAMA Netw. Open. 2020;3:e1919697. doi: 10.1001/jamanetworkopen.2019.19697. - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network Head and Neck Cancers (4.2024) [(accessed on 8 January 2024)]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
    1. Adelstein D.J., Li Y., Adams G.L., Wagner H., Jr., Kish J.A., Ensley J.F., Schuller D.E., Forastiere A.A. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 2003;21:92–98. doi: 10.1200/JCO.2003.01.008. - DOI - PubMed
    1. Bernier J., Cooper J.S., Pajak T.F., van Glabbeke M., Bourhis J., Forastiere A., Ozsahin E.M., Jacobs J.R., Jassem J., Ang K.K., et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) Head Neck. 2005;27:843–850. - PubMed

LinkOut - more resources